retatrutide triple agonist glp-1 gip glucagon receptors just had its biggest data year yet. In 2026, Eli Lilly's GLP-1/GIP/glucagon receptor posted two major Phase 3 readouts: TRIUMPH-1 (obesity, 2,339 participants) showed a 28.3% average body weight Science Behind GLP 1 GIP

GLP-1Rs agonists exert neuro-humoral actions by stimulating insulin secretion and suppressing glucagon release in a glucose-dependent manner, delaying gastric emptying, and reducing appetite via central nervous system pathways

Severe hyponatremia can progress to seizures or coma

June 2, 2024

Liraglutide injection The Safety and Clinical Adiposity Liraglutide Evidence (SCALE) trial was a randomized, double-blind, multicenter, international clinical trial that included 3,731 participants who were randomly assigned 2:1 to 3 mg liraglutide or placebo, both including lifestyle modifications

As demand for weight loss treatments like Semaglutide and Tirzepatide surged, retail pharmacies provided a reliable and familiar channel for prescription fulfillment